Drug intelligence / Profile preview

SB

Development stage: Phase 2
Modality: Small Molecules
Administration: Intravenous, Intraperitoneal

Overview

SB is a natural product new drug primarily composed of Pulsatilla saponin D, extracted from a complex of traditional Korean herbal medicines including Pulsatillae radix, Panax ginseng radix, and Glycyrrhizae radix. Its active components also include Deoxypodophyllotoxin and Pulsatillic acid, derived from Pulsatilla koreana. SB exerts its anti-tumor effects by inhibiting the proliferation of human colon cancer cells and inducing apoptosis through the modulation of the AKT and mTOR signaling pathways. Additionally, it demonstrates anti-angiogenic activity by reducing the expression of Hypoxia-inducible factor 1-alpha (HIF-1α) and Vascular endothelial growth factor (VEGF).

Brand names: SB Injection
Other names: SB injection

Targets

PBP (Penicillin-binding protein family)β-lactamase

Beyond the preview

Go deeper on SB.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SB.

Explore the full profile